Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide

Earlier studies have shown the antiinflammatory effects of histamine and nitric oxide (NO) in a model of colitis induced by DSS. However, the defense system against free radicals in this model remained unclear. The aim of this study was to evaluate the effects of rebamipide, which inhibits the produ...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 1998-09, Vol.43 (9), p.143S-147S
Main Authors: IWAI, A, IWASHITA, E
Format: Article
Language:English
Subjects:
Acute Disease
Alanine - analogs & derivatives
Alanine - pharmacology
Animals
Anti-Inflammatory Agents - pharmacology
Anti-Ulcer Agents - pharmacology
Anticoagulants - adverse effects
Biological and medical sciences
Chronic Disease
Colitis - chemically induced
Colitis - drug therapy
Colitis - enzymology
Colitis - pathology
Colonoscopy
Dextran Sulfate - adverse effects
Digestive system
Drug Administration Schedule
Leukocyte Count
Male
Medical sciences
Peroxidase - drug effects
Pharmacology. Drug treatments
Quinolones - pharmacology
Rats
Rats, Sprague-Dawley
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Earlier studies have shown the antiinflammatory effects of histamine and nitric oxide (NO) in a model of colitis induced by DSS. However, the defense system against free radicals in this model remained unclear. The aim of this study was to evaluate the effects of rebamipide, which inhibits the production of free radicals, in this model using male Sprague-Dawley rats. Colitis induced by 1% DSS is characterized by slow, weak inflammation and is regarded as a chronic inflammation model. In contrast, colitis induced by 4% DSS is characterized by fast, strong inflammation and is regarded as the acute inflammation model. Endoscopic examinations, peripheral white blood cell (WBC) counts, and assays of myeloperoxidase activity (MPO) in homogenates of colon mucosa were performed after one week (4% DSS model) and eight weeks (1% DSS model). Inflammation of colon mucosa was milder in the rats given rebamipide compared with controls in both the 4% and 1% DSS model. Furthermore, peripheral WBC counts correlated with colonic MPO activity. These findings indicate that rebamipide works as an antiinflammatory agent in both acute and chronic inflammation.
ISSN:0163-2116
1573-2568